Yukihiro Isogai

TL;DR: In this paper, the role of teriparatide administration on patient outcomes following interbody fusion was evaluated in a multicenter, prospective randomized study, where patients were randomly allocated to receive either weekly terraparatide, administered subcutaneously starting at week 1, for 6 months post-operatively (the terparamaratide arm), or no terparamarkide (the control arm). Blinded radiographic evaluations were performed using dynamic radiography and computed tomography (CT).

TL;DR: In this paper, the independent predictors of osseous union after posterior lumbar interbody fusion (PLIF) were investigated in a multicenter case-control study.

TL;DR: Evaluated the frequency of change in assessment from fusion to nonfusion in the postoperative follow-up of lumbar interbody fusion, compare the late postoperative bony union rates in groups with or without early postoperative fusion, and examine the effect of postoperative teriparatide in those groups.

TL;DR: In this paper, an agent comprising parathyroid hormone as an active ingredient was used to promote synostosis after spinal interbody fusion in spinal degenerative disease, which was administered to a patient once per week.